findmyKOL

Oluwatosin Smith, MD

Basic profile

Glaucoma Associates of Texas

ORCIDNPI
RegionDallas, TX · South CentralSpecialtyOphthalmologyFocusOphthalmology
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2025Online presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Oluwatosin Smith is an Ophthalmology physician affiliated with Glaucoma Associates of Texas. OpenAlex indexes 39 publications with 1,649 citations (h-index 15).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
39publications

Distinct works indexed by OpenAlex, matched via ORCID.

1,649citations

Total citations across indexed works.

15h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
28companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

10740 N Central Expy
Suite 300
Dallas, TX 752312161

Telephone

214-360-0000

Registry record last updated 30 Mar 2017.

View the NPPES registry record

Industry payments

28 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Sensory organs

    80.5%
    Prostaglandin Analog25.7%
    Latanoprost72%Lumigan22%Travoprost6%Tafluprost1%
    Part D<11 patients
    Carbonic Anhydrase Inhibitor23.5%
    Dorzolamide-Timolol75%Dorzolamide Hcl11%Simbrinza8%Brinzolamide6%Acetazolamide1%
    Part D359 patients

    + 8 more classes in this area

  • Cardiovascular

    12%
    Beta blocker12%
    Timolol Maleate100%
    Part D<11 patients
  • Nervous system

    3.3%
    Cholinergic Receptor Agonist3.3%
    Pilocarpine Hcl100%
    Part D102 patients
Where care is delivered (Part B)2.2% facility · 97.8% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”